CordenPharma has been continuously investing in their facilities in Switzerland, France, Italy and the U.S. to contribute to the lipid supply chain needed for the increasing demand of mRNA COVID-19 vaccines. As part of this long-term strategy, CordenPharma is investing in an expansion of its specialty lipids production at CordenPharma Chenôve (FR) using Supercritical Fluid Chromatography (SFC) technology for compound separation, which is an efficient and cost-effective process for purifying lipi...